GENPAT77 PHARMACOGENETICS AG has a total of 27 patent applications. Its first patent ever was published in 2001. It filed its patents most often in Australia, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are TANOX INC, TOPOTARGET SWITZERLAND SA and SUPPREMOL GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 8 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Canada | 4 | |
#5 | China | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Utku Nalan | 25 |
#2 | Nalan Utku | 2 |
#3 | Schlawinsky Mirko | 2 |
#4 | Warnke Peter Christian | 1 |
Publication | Filing date | Title |
---|---|---|
WO2007147623A2 | A novel target in the treatment of cytokine release syndrome | |
CN101268373A | TIRC7 as marker for detecting early immune activation | |
CN101262875A | Peptides capable of modulating the function of TIRC7 | |
AU2003233197A1 | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis | |
WO03054019A2 | Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases | |
AU2002366746A1 | Anti-tirc7 antibodies in therapy of inflammatory diseases | |
AU2002360946A1 | Use of T-cell immune response cDNA 7 (TIRC7) for modulation of angiogenesis and/or neovascularization | |
AU6388801A | Uses of tgap7 for the modulation of leucocyte activation |